ネクセラファーマの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2022/03/31 | 1,446 | 1,448 | 1,404 | 1,415 | -33 | -2.3% | 724,900 |
2022/03/30 | 1,470 | 1,472 | 1,433 | 1,448 | -6 | -0.4% | 802,300 |
2022/03/29 | 1,453 | 1,469 | 1,437 | 1,454 | +14 | +1% | 558,000 |
2022/03/28 | 1,487 | 1,487 | 1,426 | 1,440 | -49 | -3.3% | 872,000 |
2022/03/25 | 1,483 | 1,494 | 1,449 | 1,489 | +20 | +1.4% | 746,400 |
2022/03/24 | 1,454 | 1,472 | 1,434 | 1,469 | +7 | +0.5% | 520,200 |
2022/03/23 | 1,483 | 1,492 | 1,447 | 1,462 | -2 | -0.1% | 917,400 |
2022/03/22 | 1,494 | 1,494 | 1,456 | 1,464 | -26 | -1.7% | 502,400 |
2022/03/18 | 1,476 | 1,520 | 1,470 | 1,490 | +19 | +1.3% | 1,026,300 |
2022/03/17 | 1,476 | 1,477 | 1,439 | 1,471 | +25 | +1.7% | 891,800 |
2022/03/16 | 1,402 | 1,453 | 1,401 | 1,446 | +74 | +5.4% | 934,600 |
2022/03/15 | 1,363 | 1,388 | 1,342 | 1,372 | +11 | +0.8% | 826,700 |
2022/03/14 | 1,365 | 1,395 | 1,340 | 1,361 | -11 | -0.8% | 637,200 |
2022/03/11 | 1,392 | 1,396 | 1,347 | 1,372 | -19 | -1.4% | 636,800 |
2022/03/10 | 1,387 | 1,398 | 1,369 | 1,391 | +49 | +3.7% | 728,100 |
2022/03/09 | 1,350 | 1,360 | 1,301 | 1,342 | +7 | +0.5% | 978,500 |
2022/03/08 | 1,311 | 1,361 | 1,300 | 1,335 | +15 | +1.1% | 1,338,600 |
2022/03/07 | 1,325 | 1,355 | 1,301 | 1,320 | -44 | -3.2% | 1,154,200 |
2022/03/04 | 1,430 | 1,438 | 1,342 | 1,364 | -69 | -4.8% | 1,412,700 |
2022/03/03 | 1,460 | 1,473 | 1,412 | 1,433 | -7 | -0.5% | 983,000 |
2022/03/02 | 1,427 | 1,469 | 1,416 | 1,440 | +9 | +0.6% | 1,406,000 |
2022/03/01 | 1,414 | 1,439 | 1,384 | 1,431 | +12 | +0.8% | 1,516,500 |
2022/02/28 | 1,399 | 1,433 | 1,380 | 1,419 | +5 | +0.4% | 958,600 |
2022/02/25 | 1,375 | 1,421 | 1,355 | 1,414 | +81 | +6.1% | 1,497,600 |
2022/02/24 | 1,407 | 1,414 | 1,311 | 1,333 | -77 | -5.5% | 2,403,900 |
2022/02/22 | 1,381 | 1,451 | 1,380 | 1,410 | +5 | +0.4% | 1,300,500 |
2022/02/21 | 1,420 | 1,424 | 1,377 | 1,405 | -50 | -3.4% | 1,351,800 |
2022/02/18 | 1,409 | 1,461 | 1,403 | 1,455 | +16 | +1.1% | 1,148,100 |
2022/02/17 | 1,488 | 1,493 | 1,424 | 1,439 | -38 | -2.6% | 1,382,400 |
2022/02/16 | 1,510 | 1,512 | 1,466 | 1,477 | -3 | -0.2% | 1,155,300 |
2022/02/15 | 1,470 | 1,519 | 1,464 | 1,480 | ±0 | ±0% | 1,049,100 |
2022/02/14 | 1,432 | 1,480 | 1,375 | 1,480 | -52 | -3.4% | 1,868,200 |
2022/02/10 | 1,515 | 1,539 | 1,505 | 1,532 | +40 | +2.7% | 1,124,900 |
2022/02/09 | 1,479 | 1,500 | 1,455 | 1,492 | +32 | +2.2% | 881,500 |
2022/02/08 | 1,470 | 1,493 | 1,449 | 1,460 | -2 | -0.1% | 787,600 |
2022/02/07 | 1,498 | 1,520 | 1,456 | 1,462 | -38 | -2.5% | 1,018,600 |
2022/02/04 | 1,515 | 1,524 | 1,478 | 1,500 | -23 | -1.5% | 1,207,300 |
2022/02/03 | 1,525 | 1,548 | 1,502 | 1,523 | -42 | -2.7% | 1,108,400 |
2022/02/02 | 1,528 | 1,575 | 1,528 | 1,565 | +64 | +4.3% | 1,030,800 |
2022/02/01 | 1,531 | 1,556 | 1,482 | 1,501 | -16 | -1.1% | 1,645,800 |
2022/01/31 | 1,493 | 1,525 | 1,464 | 1,517 | +47 | +3.2% | 1,671,200 |
2022/01/28 | 1,510 | 1,529 | 1,437 | 1,470 | -18 | -1.2% | 1,638,600 |
2022/01/27 | 1,517 | 1,555 | 1,464 | 1,488 | -30 | -2% | 1,866,400 |
2022/01/26 | 1,505 | 1,539 | 1,480 | 1,518 | +17 | +1.1% | 1,338,400 |
2022/01/25 | 1,563 | 1,575 | 1,495 | 1,501 | -63 | -4% | 1,572,800 |
2022/01/24 | 1,549 | 1,579 | 1,523 | 1,564 | +12 | +0.8% | 1,263,400 |
2022/01/21 | 1,580 | 1,585 | 1,507 | 1,552 | -70 | -4.3% | 2,127,000 |
2022/01/20 | 1,592 | 1,630 | 1,570 | 1,622 | +34 | +2.1% | 1,531,700 |
2022/01/19 | 1,608 | 1,632 | 1,579 | 1,588 | -44 | -2.7% | 1,429,600 |
2022/01/18 | 1,654 | 1,680 | 1,618 | 1,632 | -33 | -2% | 1,488,400 |
651~
700
件表示中 / 4976件
類似銘柄と比較する
現在ご覧いただいている「ネクセラファーマ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
持田薬 | 331,500円 | +3.0% | +27.5% | 2.41% | 20.99倍 | 0.91倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
JCRファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
市場注目の銘柄
チャート関連のコラム